Rubicon Research Limited, a provider of contract formulation development services to pharmaceutical companies, announced its Q4 FY2026 and FY2026 results.

The Company reported a strong financial performance for the quarter and year ended March 31, 2026, with net profit for the quarter rising 112 percent.

Revenue growth for the company was broad-based, with the top 5 products contributing 39% of revenue in Q4 FY2026, up from 34% in Q1 FY2026.

USD revenue for Q4 FY2026 stood at $56 million, up 35% year-on-year, with approximately 98% of total revenue denominated in USD.

Revenue from operations for Q4 FY2026 increased 44 percent to ₹5.14 billion compared to ₹3.58 billion in Q4 FY2025, driven by robust growth across the pharmaceutical product portfolio.

Rubicon reported a 112% rise in Q4 FY2026 net profit to ₹768 million and an 84% increase in FY2026 net profit to ₹2.47 billion.

EPS (Earnings Per Share) for the year increased to ₹15.52 from ₹8.82 in the prior year.

The board has recommended a dividend of 150%, which is ₹1.50 per share. This amounts to 10% payout ratio.

Rubicon Research Limited Q4 FY2026

Management explained that the Pithampur site has been qualified and filed with the USFDA, with production ramp-up expected in Q1 CY27.

It also said that revenue traction is likely to continue to be stronger than anticipated, which in turn would require a commensurate increase in revenue from outsourced manufacturing as compared to what we had previously envisaged.

Company Overview & Others

Overview: Rubicon Research Ltd. is a pharmaceutical formulations company, driven by innovation through research and development (R&D). The company planned an IPO in October 2025.

Market Cap: Rubicon Research has a total market capitalization of ₹16,500 crore as of May 30, 2026, according to the NSE data.

Technical: The stock is well placed above its 20-, 50-, and 100-day simple moving averages (SMAs).

Price Performance: On a year-to-date basis, Rubicon Research’s share increased by 48%. However, the company’s shares have been trading 28% higher over the last three months.

Also Read

GST collections April 2026

Disclaimer: This article is purely for informational purposes. While much time and effort is made to provide the information, I (Vishal Dalwadi) or (FinBlab) do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.

The post Rubicon Research Limited Q4 FY2026 appeared first on Upcoming ipos: Latest news on stocks, economy & finance.